MayoComplete Solid Tumor Panel: Kevin C. Halling, M.D., Ph.D.

Kevin C. Halling, M.D., Ph.D., co-director of Mayo Clinic’s Genomics Lab, discusses the MayoComplete Solid Tumor Panel, a next-generation sequencing assay that assesses for mutations in 514 genes shown to have clinical significance. Utilizing a hybrid capture method and TSO 500 reagent, the test uses both RNA and DNA to detect genetic alterations, such as tumor mutation burden and microsatellite instability, that can lend insight on treatment tolerance and response.

Show Notes

(00:31):

Before we get started, Dr. Halling, could you provide us with a little bit about you and your background?

 

(01:11):

Would you like to give us a basic summary of this test?

(02:43):

So in talking about patients, can you tell us which patients should have this testing? And when it is typically performed?

 

(05:01):

Do you want to talk about some of the guidelines that were used to shape the genes included in this panel?

 

(05:36):

Can you tell us a bit about the alternative test options that are available and how they compare to this large panel?

 

(06:42):

So I know most other panels on the market assess for mutations and fusions. Is there a reason why our panel also looks at amplifications and are certain subset of the genes?

 

(07:29):

So do you want to talk about how this panel offers some benefits over other large panels in the market?

 

(08:46):

Let's talk a little bit about how the results of this test can be used in patient care.

What is Answers from the Lab?

A Mayo Clinic curated podcast sharing Mayo Clinic knowledge and advancements on the state of testing, science, and people who are making it happen behind the scenes.